Overview of the Osteosarcoma pipeline landscape
Global
Markets Direct's, Osteosarcoma - Pipeline Review, H2 2016', provides an
overview of the Osteosarcoma pipeline landscape.
The report provides
comprehensive information on the therapeutics under development for
Osteosarcoma, complete with analysis by stage of development, drug target,
mechanism of action (MoA), route of administration (RoA) and molecule type. The
report also covers the descriptive pharmacological action of the therapeutics,
its complete research and development history and latest news and press
releases. Additionally, the report provides an overview of key players involved
in therapeutic development for Osteosarcoma and features dormant and
discontinued projects.
The report
helps in identifying and tracking emerging players in the market and their
portfolios, enhances decision making capabilities and helps to create effective
counter strategies to gain competitive advantage.
Complete
report on Osteosarcoma - Pipeline Review, H2 2016 addition with 37 market data
tables and 15 figures, spread across 223 pages is http://www.rnrmarketresearch.com/osteosarcoma-pipeline-review-h2-2016-market-report.html
This report
features investigational drugs from across globe covering over 20 therapy areas
and nearly 3,000 indications. The report is built using data and information
sourced from Global Markets Direct's proprietary databases, company/university
websites, clinical trial registries, conferences, SEC filings, investor
presentations and featured press releases from company/university sites and
industry-specific third party sources. Drug profiles featured in the report
undergoes periodic review following a stringent set of processes to ensure that
all the profiles are updated with the latest set of information. Additionally,
various dynamic tracking processes ensure that the most recent developments are
captured on a real time basis
Drugs Profile Discussed in this Research:
3D-QM, 3D-QMS,
ADXS-HER2, aldoxorubicin hydrochloride, AM-7209, AU-101, AV-203, axitinib,
cabozantinib s-malate, Cellular Immunotherapy for GD2 Expressing Solid Tumors,
Cellular Immunotherapy to Target HER2 for Glioblastoma Multiforme and
Osteosarcoma, Cellular Immunotherapy to Target MAGE-A1, MAGE-A3 and NY-ESO-1
for Oncology, celyvir, CGS-200, cisplatin SR, dihydroartemisinin, dinutuximab,
everolimus ,glembatumumab vedotin,irinotecan hydrochloride,ligerin ,LLL-12,Modufolin,Monoclonal
Antibody for Osteosarcoma ,Monoclonal Antibody to Inhibit GD2 for Oncology
,Monoclonal Antibody to Target Ganglioside GD2 for Neuroblastoma and
Osteosarcoma,MPE-8.3 ,NP-137 ,OBP-702,Oligonucleotides to Inhibit
Thymidylate Synthase and Dihydrofolate Reductase for Osteosarcoma and Colon
Cancer, pazopanib hydrochloride , pembrolizumab , Peptide to Target
COX-2 and MAS-GPCR for Oncology, radium Ra 223 dichloride, RSF-101 ,
S-588410, SEN-461, Small Molecules to Agonize Vitamin D3 Receptor for
Osteosarcoma, Small Molecules to Inhibit CaMKII for Osteosarcoma, T-2GES,
Vaccine for Osteosarcoma
Companies Discussed/Mentioned in this Research:
Advaxis,
Inc, Amgen Inc., AVEO Pharmaceuticals, Inc., Bayer
AG, Bellicum Pharmaceuticals, Inc., Celldex Therapeutics,
Inc., CytRx Corporation, Eleison Pharmaceuticals LLC, Exelixis,
Inc., Isofol Medical AB, MediaPharma s.r.l., Merck & Co.,
Inc,Merrimack Pharmaceuticals, Inc., Netris Pharma S.A.S., Novartis
AG, Oncolys BioPharma Inc, Pfizer Inc., Shionogi & Co.,
Ltd., Teijin Pharma Limited, United Therapeutics Corporation,
Inquire
before buying for this report
(This is a
premium report price at US$2000 for a single user PDF license).
Scope:
- The report provides a
snapshot of the global therapeutic landscape of Osteosarcoma
- The report reviews pipeline
therapeutics for Osteosarcoma by companies and universities/research
institutes based on information derived from company and industry-specific
sources
- The report covers pipeline
products based on various stages of development ranging from
pre-registration till discovery and undisclosed stages
- The report features
descriptive drug profiles for the pipeline products which includes,
product description, descriptive MoA, R&D brief, licensing and
collaboration details & other developmental activities
- The report reviews key
players involved Osteosarcoma therapeutics and enlists all their major and
minor projects
- The report assesses
Osteosarcoma therapeutics based on drug target, mechanism of action (MoA),
route of administration (RoA) and molecule type
- The report summarizes all
the dormant and discontinued pipeline projects
- The report reviews latest
news related to pipeline therapeutics for Osteosarcoma
Reasons
to buy
- Gain strategically
significant competitor information, analysis, and insights to formulate
effective R&D strategies
- Identify emerging players
with potentially strong product portfolio and create effective
counter-strategies to gain competitive advantage
- Identify and understand
important and diverse types of therapeutics under development for Osteosarcoma
- Identify potential new
clients or partners in the target demographic
- Develop strategic
initiatives by understanding the focus areas of leading companies
- Plan mergers and
acquisitions effectively by identifying key players and it's most
promising pipeline therapeutics
- Devise corrective measures
for pipeline projects by understanding Osteosarcoma pipeline depth and
focus of Indication therapeutics
- Develop and design
in-licensing and out-licensing strategies by identifying prospective
partners with the most attractive projects to enhance and expand business
potential and scope
- Modify the therapeutic
portfolio by identifying discontinued projects and understanding the
factors that drove them from pipeline
About
Us:
RnRMarketResearch.com
is an online database of market research reports offer in-depth analysis of
over 5000 market segments. The library has syndicated reports by leading market
research publishers across the globe and also offer customized market research
reports for multiple industries.
Comments
Post a Comment